Health
Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection – News-Medical.Net
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked immunosorbent assays (“ELISAs”) are very common research tools used to detect and quantify a target of interest in a wide range of samples. Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test…
-
Noosa News20 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News23 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General23 hours agoDairy farmers devastated by floods across parts of New South Wales
-
General19 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity